Flex Pharma, Inc. (FLKS): Christoph H Westphal , CEO of Flex Pharma, Inc. purchased 33,400 shares on May 17, 2016. The Insider buying transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were purchased at $11.10 per share for a total value of $370,708.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 17, 2016, Christoph H Westphal (CEO) purchased 15,469 shares at $10.24 per share price.On Mar 16, 2016, Michelle Stacy (director) purchased 2,585 shares at $9.63 per share price.Also, On Mar 15, 2016, Fund Ii, L.p. Longwood (10% owner) purchased 89,680 shares at $7.00 per share price.On Mar 15, 2016, Thomas Wessel (Chief Medical Officer) purchased 20,000 shares at $8.14 per share price.
Flex Pharma Inc: On Thursday, May 19, 2016 heightened volatility was witnessed in Flex Pharma Inc which led to swings in the share price. The shares opened for trading at $10.99 and hit $11.34 on the upside , eventually ending the session at $11.19, with a gain of 1.73% or 0.19 points. The heightened volatility saw the trading volume jump to 63,619 shares. The 52-week high of the share price is $20.59 and the company has a market cap of $201,062 M . The 52-week low of the share price is at $6.48.
Flex Pharma Inc. is a biotechnology company that is developing treatments for exercise-associated muscle cramps nocturnal leg cramps and spasms for neuromuscular conditions. The Company focuses its drug development efforts on developing a product to treat nocturnal leg cramps. The Company’s treatment which forms the basis of both drug product and consumer product development efforts activates the transient receptor potential (TRP) cation channel receptors in primary sensory neurons in the spinal cord that enhances overall inhibitory tone in motor neurons throughout the body. The Company’s pre-clinical drug product candidates are offered for Nocturnal leg cramps and MS spasticity cervical dystonia and/or SCI spasticity. The Company’s consumer brand and products focuses athletes experiencing exercise-associated muscle cramps or EAMCs. The Company has commenced formulation and commercialization efforts of its consumer brand.